(Información remitida por la empresa firmante)
Last participant has been randomised in clinical trial 0205 investigating efficacy and safety of CT001 relative to placebo and two comparative active arms
Primary aim is to show that CT001 offers a better pain reduction and safety profile compared to the comparative arms and placebo
Top--line results are anticipated during Q4 2023 once data has been analysed
COPENHAGEN, Denmark, Sept.
